Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opening Product Labeling To Broader CE Data Is Proposed In Senate Bill

Executive Summary

Drug product labels could contain an array of comparative effectiveness data beyond well-controlled clinical trials, if Sens. Jack Reed, D-R.I., and Barbara Mikulski, D-Md., get their way

You may also be interested in...

FDA May Allow "Qualitative" Labels For Data In DTC Ads

Study of "format variations" in the brief summary of print advertisements will test different ways of presenting benefit and risk information.

FDA's DTC Survey Tweaked At PhRMA's Suggestion

Study will consider how different formats for communicating quantitative efficacy could affect consumers' understanding of print and TV ads.

PDUFA V "Wish List" From Consumers Union Includes Comparative Effectiveness Standard

Formally at the user fee negotiation table for the first time, the advocacy group wants new drugs to be tested against the "best practice" for treating a disease.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts